3/26
Positive
Late treatment study
Nanshan (钟南山) (Preprint)
Efficacy and safety of ch loroquine for treatment of COVID-19. An open-label, multi-center, non-randomized trial
197 patients. C Q effective. Day 10 viral RNA negative 91.4% HC Q versus 57.4% control. Median time to negative test 3 days versus 9 days for control.
no virological cure, ↓80.0%, p<0.0001, risk of no virological cure at day 10